The primary goal ( cardiovascular death , nonfatal myocardial infarction and nonfatal CMP ) occurred in 7.3 % ( 613 ) patients treated with saxagliptin and in 7.2 % ( 609 ) patients treated with placebo ( HR 1.00 , p < 0.001 for non inferiority ) .